report fiscal adjust ep
consensu expect lower forecast higher-than-
anticip adjust oper expens account
downsid rel forecast
coo fiscal revenu increas year-over-year million
consensu expect million similar
estim million quarter coopervis achiev organ
growth estim led asia pacif
year-over-year america year-over-year contrast
coopersurg revenu slightli lower anticip
million versu million forecast strength offic surgic
product off-set weak fertil
year estim higher expens
invest drive sale key larg retail account drove
differ rel forecast
narrow revenu guidanc million
million reflect currenc chang addit compani
reduc adjust ep guidanc
notabl currenc chang account ep headwind versu
prior guidanc strength organ
growth lower tax rate larg off-set plan spend drive
organ growth particularli key larg retail account coopervis
histor lower presenc
provid formal guidanc compani suggest
earn call low-single-digit adjust ep growth next year
ballpark rang given expect higher adjust tax rate
versu ep headwind currenc chang
lower adjust ep estim
respect better reflect coo
commentari regard currenc headwind tax
assum adjust tax rate previous
total debt total asset
encourag coopervis improv organ growth
compani decis invest grow key larg retail account segment
point strength made necessari invest distribut
packag manufactur sale forc ideal product clariti
penetr segment invest intermediate-term
opportun misight myopia control think path toward sustain
above-market organ growth coopervis clearer investor
currenc chang tax present headwind remain
confid coo long-term growth opportun maintain buy
rate increas price target slightli
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect lower
forecast higher-than-anticip adjust oper expens account
downsid rel forecast
coo fiscal revenu increas year-over-year million consensu
expect million similar estim million quarter total compani organ
growth roughli estim led strength coopervis addit acquisit
growth approxim better anticip driven strength paragard contrast
revenu contribut currenc chang modestli lower model million versu
million forecast lead in-lin revenu versu estim
divis standpoint coopervis achiev fiscal organ growth approxim
estim
quarter coopervis result led broad strength across geographi includ pro forma organ
growth asia pacif america emea product standpoint daili silicon
hydrogel lens experienc particularli robust sale year-over-year pro forma organ growth basi
combin sale silicon hydrogel lens biofin avaira also improv year-over-year
addit favor fiscal result manag also discuss effort acceler coopervis
sale key larg retail account compani earn call point coopervis made
necessari invest support growth key larg retail account start see initi win across
geographi market share win appear come primarili alcon base report calendar
result competitor notabl still earli key account initi benefit initi
contract win fulli seen compani fiscal result well like futur
contract help give investor comfort coopervis abil maintain above-market growth
despit upcom competit daili silicon hydrogel len launch alcon bausch lomb
cooper compani inc total compani organ growth analysi compani report northcoast research exclud aim fiscal organ growth analysisnorthcoast sale organ growth dollar organ growthcor coopervis paragon pro-forma coopervis compani report northcoast research estim
coopersurg report fiscal pro forma organ growth quarter divis result led
strong acquisit revenu paragard year-over-year roughli million moreov due
continu momentum decid increas promot advertis support paragard well
number sale rep better capit product opportun addit strength paragard
coopersurg achiev roughli mid-single-digit pro forma organ growth core busi remov
fiscal sale two fertil product categori carrier screen non-invasive prenat test
compani decid exit year
exclud carrier screen non-invasive prenat test prior year revenu estim
coopersurg fiscal organ growth closer neg flat forecast
quarter compani fertil busi experienc disrupt manag attent focus
complet exit carrier screen non-invasive prenat test notabl expect improv
fertil sale estim year-over-year includ carrier screen non-invasive
prenat test prior year base move past transit posit note fiscal
strong quarter coopersurg core offic surgic product roughli organ exclud
paragard acquisit aid strong sale endose hysteroscop compani next-gener
coo fiscal adjust oper margin increas bp year-over-year
estim higher expens invest drive sale key account drove differ
rel forecast notabl compani adjust gross margin rel strong bp year-over-
year aid paragard acquisit well manufactur effici product mix
narrow revenu guidanc million million reflect currenc
chang addit compani reduc adjust ep guidanc
notabl currenc chang account ep headwind versu prior guidanc
strength organ growth lower tax rate larg off-set plan spend drive
organ growth particularli key larg retail account coopervis histor lower presenc
provid formal guidanc compani suggest earn call low-single-digit
adjust ep growth next year ballpark rang given expect higher adjust tax rate
versu ep headwind currenc chang
lower adjust ep estim
respect better reflect coo commentari regard currenc headwind tax
assum adjust tax rate previous
overal encourag coopervis improv organ growth compani decis invest
grow key larg retail account segment point strength made necessari invest
distribut packag manufactur sale forc ideal product clariti penetr
segment invest intermediate-term opportun misight myopia control think
path toward sustain above-market organ growth coopervis clearer investor
currenc chang tax present headwind remain confid coo long-term growth
opportun maintain buy rate increas price target slightli
cooper compani inc annual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg amort oper oper net interest interest incom incom incom incom tax minor net incom extra net margin extra extra net net wghd com share ep ep revenu growth adjust ep growth began exclud amort intang adjust ep follow sauflon acquisitionsourc compani report northcoast research estim disclosur
